Ventac Partners
Mikael Oerum has extensive experience in various leadership roles within the biotech and pharmaceutical industries. Mikael has served as the Chairman of the Board of Directors for multiple companies, including QMed Consulting A/S, Cenexum Technologies, Orbit Genomics, Inc., RhoVac AB, and Amunix Pharmaceuticals, Inc. Oerum has also been a Board Member for IXALTIS SA and an Advisory Board Member for Cube Labs, where they have contributed to the development and growth of these organizations. Additionally, they are the founder and partner of Ventac Partners, an international company specializing in identifying innovative discoveries and advancements in pharma and diagnostics. Oerum has successfully led strategic initiatives and turnarounds for companies such as Neuroscience Technologies S.L.P. and Neuroscience Technologies Ltd. and Avexxin AS (now Coegin Pharma AB). Mikael'sexpertise lies in building organizations, securing funding, and driving business growth in the healthcare technology sector.
Mikael Oerum has an education in banking, finance, and law, as well as an officers education. No specific details about the start or end year, degree name, or field of study are provided.
This person is not in any teams
This person is not in any offices
Ventac Partners
1 followers
With offices across Europe, United States and Asia and with our multi-disciplinary Partner and Advisor teams, Ventac Partners strives to provide its clients superior global services delivered locally. Covering Biotech, Pharma and Medtech, we offer hands-on experience and skills required to drive innovative technology-based projects from the laboratory to the market. Over the last 15 years, we have experienced a steadily growing business with industry and academic institutions, we have founded, incorporated and exited several companies together with our partners and investors and consulted on hundreds of different early stage or advanced projects. Ventac Partners is continuously expanding its international presence and remains committed to generate value to its clients and portfolio company partners and investors.